Equities researchers at LADENBURG THALM/SH SH initiated coverage on shares of Renovacor (NYSE:RCOR) in a note issued to investors on Thursday, The Fly reports. The brokerage set a “buy” rating on the stock.
Separately, Chardan Capital started coverage on shares of Renovacor in a research note on Friday, October 1st. They issued a “buy” rating and a $20.00 target price for the company.
RCOR opened at $7.93 on Thursday. Renovacor has a fifty-two week low of $7.49 and a fifty-two week high of $11.12.
Renovacor Inc is an early?stage biotechnology company developing adeno-associated virus based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants. Renovacor Inc, formerly known as Chardan Healthcare Acquisition 2 Corp., is based in NEW YORK.
See Also: How To Calculate Debt-to-Equity Ratio
Receive News & Ratings for Renovacor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renovacor and related companies with MarketBeat.com's FREE daily email newsletter.